CCL

Összesen 13 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM035383
035-os BibID:WOS:000088898401139
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:Examination of bone mineral density in men with systemic lupus erythematosus : results of a one-year prospective controlled study / H. P. Bhattoa, P. Bettembuk, E. Kiss, A. Balogh
Dátum:2000
ISSN:0884-0431
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Endocrinology & Metabolism
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Bone and Mineral Research. Supplement. - 15 : 1 (2000), p. S420. -
További szerzők:Bettembuk Péter Kiss Emese (1960-) (belgyógyász, immunológus) Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos)
Borító:

2.

001-es BibID:BIBFORM035380
035-os BibID:WOS:000170709001164
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:Hormone replacement therapy in osteopenic postmenopausal women with systemic lupus erythematosus - Bone mineral density and biochemical markers of bone turnover at baseline / Bhattoa, H. P., Kiss, E., Bettembuk, P., Balogh, Á.
Dátum:2001
ISSN:0884-0431
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Endocrinology & Metabolism
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Bone And Mineral Research. Supplement. - 16 : 1 (2001), p. S415. -
További szerzők:Kiss Emese (1960-) (belgyógyász, immunológus) Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos)
Borító:

3.

001-es BibID:BIBFORM035376
035-os BibID:WOS:000177952800624
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:Bone mineral density changes in a one year placebo controlled double blind randomized trial of hormone replacement therapy in postmenopausal systemic lupus erythematosus patient / Bhattoa, H. P., Bettembuk, P., Balogh, Á., Szegedi, Gy., Kiss, E.
Dátum:2002
ISSN:0884-0431
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Endocrinology & Metabolism
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Bone and Mineral Research. Supplement. - 17 : 1 (2002), p. S272. -
További szerzők:Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Borító:

4.

001-es BibID:BIBFORM035327
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:Bone mineral density in women with systemic lupus erythematosus / H. P. Bhattoa, P. Bettembuk, A. Balogh, G. Szegedi, E. Kiss
Dátum:2002
ISSN:0770-3198
Megjegyzések:The aim of this cross-sectional study was to determine the prevalence of reduced bone mineral density (BMD) in a group of female SLE patients and to identify factors predictive of reduced BMD. Femoral neck (FN) and lumbar spine (LS) dual-energy X-ray absorptiometry results wer evaluated in 79 pre- and postmenopausal women with SLE aged (mean, range) 49 (22-73) years). Variables evaluated were disease duration, SLEDAI, current and cumulative corticosteroid dose, Steinbrocker's functional classification, use of immunosuppressive agents, and history of fracture due to minor trauma. A T-score of ?ë♯n 1.0 was found in 61.9% at the LS and 48.3% at the FN, and 18 (23.7%) patients belonged to the category of osteoporosis at LS, compared to only three (5.4%) patients at FN. A statistical difference (P = 0.014) was found when comparing LS BMD in pre- and postmenopausal patients. LS BMD had a significant correlation with daily and cumulative steroid dose (P = 0.016 and 0.031, respectively). There was a significant difference in LS BMD between the daily steroid dose group receiving ?ë♯n 7.5 and those receiving > 7.5. mg/day (P = 0.008), and also in FN BMD comparing groups on 0 and > 7.5 mg/day (P = 0.022). There was significant difference in LS and FN BMD between patients in Steinbrocker classes I and III (P = 0.016 and 0.005, respectively). No significant correlation was found in either subgroup between BMD and other studied parameters. We concluded that the prevalence of reduced bone mass at LS is pronounced among postmenopausal women with SLE, in those with a high Steinbrocker functional classification and those on a high daily steroid dose. Therefore, these patients should be considered as a high-risk group deserving regular spinal BMD scans and therapy in time to prevent vertebral fractures.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Bone mineral density
Female
Glucocorticoids
Osteoporosis
Systemic lupus erythematosus
corticosteroid
immunosuppressive agent
adult
aged
article
bone density
bone mass
bone mineral
bone scintiscanning
controlled study
correlation analysis
disease classification
disease duration
dose response
dual energy X ray absorptiometry
female
femur neck
high risk patient
human
lumbar spine
osteoporosis
postmenopause
prediction
premenopause
prevalence
priority journal
scoring system
systemic lupus erythematosus
vertebra fracture
age distribution
cohort analysis
comparative study
cross-sectional study
hospitalization
Hungary
middle aged
physiology
probability
radiodensitometry
risk assessment
risk factor
Adrenal Cortex Hormones
Adult
Age Distribution
Aged
Bone Density
Cohort Studies
Comparative Study
Cross-Sectional Studies
Densitometry, X-Ray
Female
Human
Hungary
Lupus Erythematosus, Systemic
Middle Age
Osteoporosis
Prevalence
Probability
Risk Assessment
Risk Factors
Severity of Illness Index
Support, Non-U.S. Gov't
Humans
Middle Aged
Megjelenés:Clinical Rheumatology. - 21 : 2 (2002), p. 135-141. -
További szerzők:Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

5.

001-es BibID:BIBFORM035329
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus / Harjit Pal Bhattoa, Emese Kiss, Peter Bettembuk, Adam Balogh
Dátum:2001
ISSN:0172-8172
Megjegyzések:The aim of this study was to evaluate bone mineral density (BMD), biochemical markers of bone turnover, and hormone levels in men with systemic lupus erythematosus (SLE). BMD at L2-L4 lumbar vertebrae (LS), left proximal femur neck, and radius at the ultradistal and mid-33% region was measured by dual-energy X-ray absorptiometry in 23 men with SLE (mean age, disease duration, and cumulative corticosteroid dose were 45.6 years, 11.9 years, and 33.410 g, respectively) and 40 healthy, age- and sex-matched controls. Biochemical markers of bone turnover, parathyroid hormone and 25-hydroxyvitamin D (25-OH-D), testosterone, and dehydroepiandrosterone sulfate (DHEAS) levels were measured. There was no difference in BMD between the SLE and control group. The prevalence of osteoporosis was 17.4% (4 out of 23), found at LS. Biochemical markers of bone turnover were within the reference range. There was a high prevalence of hypovitaminosis D (65.2%), hypotestosteronism (62.5%), and hypodehydroepiandrosterone sulfate (100%). There was no correlation between BMD and duration of disease, corticosteroid doses, SLE Disease Activity Index (SLEDAI), SLE Collaboration Clinics/American College of Rheumatology (SLICC/ARC) damage index, or markers of bone turnover. Bone-specific alkaline phosphatase (BSAP) (r, -0.500; P = 0.018) and DHEAS (r, -0.511; P = 0.013) correlated with daily corticosteroid dose. Despite corticosteroid therapy, bone mass in men with SLE was not decreased.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Biochemical markers of bone turnover
Bone mineral density
Corticosteroids
Hormones
Men
Systemic lupus erythematosus
25 hydroxyvitamin D
alkaline phosphatase
biological marker
corticosteroid
prasterone sulfate
testosterone
adult
aged
article
body mass
bone density
bone mineral
bone turnover
clinical article
controlled study
disease activity
disease duration
dual energy X ray absorptiometry
femur neck
human
lumbar vertebra
male
osteoporosis
priority journal
systemic lupus erythematosus
vitamin deficiency
Aged
Alkaline Phosphatase
Bone Density
Bone Remodeling
Cross-Sectional Studies
Female
Glucocorticoids
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Megjelenés:Rheumatology International. - 21 : 3 (2001), p. 97-102. -
További szerzők:Kiss Emese (1960-) (belgyógyász, immunológus) Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

6.

001-es BibID:BIBFORM035324
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients : a randomized, double-blind, placebo-controlled trial / H. P. Bhattoa, P. Bettembuk, A. Balogh, Gy. Szegedi, E. Kiss
Dátum:2004
ISSN:0937941X
Megjegyzések:We studied the effect of 1-year transdermal estrogen replacement therapy (ERT) on bone mineral density (BMD) and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus (SLE) patients in a randomized, double-blind, placebo-controlled trial. SLE patients were randomly allocated to treatment (estradiol; 50 ??g transdermal 17??-estradiol; n = 15) or placebo (n = 17) group. Both groups received 5 mg continuous oral medroxyprogesterone acetate, 500 mg calcium and 400 IU vitamin D3, L1-L4 spine (LS), left femur and total hip BMD were measured at baseline and at 6 and 12 months. Serum osteocalcin (OC) and degradation products of C-terminal telopeptides of type-I collagen (CTx) levels were measured at baseline and 3, 6, 9, and 12 months. There was a significant difference in the percentage change of LS BMD at 6 months between the two groups (103.24 ?? 3.74% (estradiol group) vs 98.99 ?? 3.11% (placebo group); P < 0.005). There was a significant decrease within the estradiol group in the CTx levels between baseline and all subsequent visits (P < 0.05). There was no significant difference in SLE disease activity index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) damage index and corticosteroid dose during the study period, Transdermal estradiol may prevent bone loss in postmenopausal SLE women at the lumbar spine and femur, with no increase in disease activity among postmenopausal SLE women receiving transdermal ERT. The high dropout rate (8/15) leads us to the conclusion that efficacy of HRT in a high-risk group such as SLE women can be attained only in a small number of patients, provided all inclusion/exclusion criteria are strictly adhered to.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Biochemical markers of bone turnover
Bone mineral density
Osteopenia
Postmenopausal Systemic lupus erythematosus
Transdermal estrogen replacement therapy
biological marker
calcium
carboxy terminal telopeptide
collagen type 1
corticosteroid
estradiol
medroxyprogesterone acetate
osteocalcin
placebo
vitamin D
adult
aged
article
bone density
bone mineral
bone turnover
carboxy terminal sequence
clinical trial
controlled clinical trial
controlled study
disease activity
double blind procedure
drug effect
drug efficacy
estrogen therapy
female
femur
hip
human
lumbar spine
medical society
osteolysis
osteopenia
postmenopause
priority journal
prophylaxis
protein blood level
randomization
randomized controlled trial
systemic lupus erythematosus
Administration, Cutaneous
Adult
Aged
Biological Markers
Bone Density
Bone Remodeling
Double-Blind Method
Estradiol
Estrogen Replacement Therapy
Female
Femur Neck
Hip Joint
Humans
Lumbar Vertebrae
Lupus Erythematosus, Systemic
Middle Aged
Osteoporosis, Postmenopausal
egyetemen (Magyarországon) készült közlemény
Megjelenés:Osteoporosis International. - 15 : 5 (2004), p. 396-404. -
További szerzők:Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM035386
035-os BibID:WOS:000082347101021
Első szerző:Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:Bone mineral density in women with systemic lupus erythematosus / H. P. Bhattoa, P. Bettembuk, E. Kiss, A. Balogh
Dátum:1999
ISSN:0884-0431
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Endocrinology & Metabolism
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Bone and Mineral Research. Supplement. - 14 : 1 (1999), p. S388. -
További szerzők:Bettembuk Péter Kiss Emese (1960-) (belgyógyász, immunológus) Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos)
Borító:

8.

001-es BibID:BIBFORM035328
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:Pregnancy in women with systemic lupus erythematosus / Emese Kiss, Harjit P. Bhattoa, Peter Bettembuk, Adam Balogh, Gyula Szegedi
Dátum:2002
ISSN:0301-2115
Megjegyzések:Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder which may be affected by hormonal changes, such as those of pregnancy. Women with SLE have increased adverse pregnancy outcomes. Study design: A retrospective analysis of the gynecologic and immunologic case history of 140 women with SLE and the outcome of 263 pregnancies in 99 women with SLE. Results: In patients diagnosed with SLE, the proportion of pregnancies ending with live birth at term decreased to one-third compared with three quarters in those without a diagnosis of SLE and the incidence of pre-term deliveries and spontaneous abortions increased by 6.8 and 4.7 times, respectively. When SLE was associated with secondary antiphospholipid (APL) syndrome, and lupus anticoagulant (LA) or ??2-glycoprotein antibodies were present, a further increase in the incidence of pregnancy loss was observed. Pregnancy did not cause a flare-up of SLE in all cases, the disease remained stable in about 30% of the patients. Lupus was mild in the majority of the women who carried out their pregnancy to term. We also observed mothers with active SLE who successfully carried out pregnancies to term. Conclusion: These findings accord with previous literature and should inform rheumatologists, obstetricians and neonatologists who guide patients in their reproductive decisions.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Lupus anticoagulant
Pregnancy
Spontaneous abortion
Systemic lupus erythematosus
lupus anticoagulant
adult
antiphospholipid syndrome
article
female
human
incidence
induced abortion
major clinical study
pregnancy
priority journal
risk
spontaneous abortion
systemic lupus erythematosus
thrombosis
Adolescent
Adult
Aged
Female
Humans
Lupus Erythematosus, Systemic
Middle Aged
Pregnancy
Pregnancy Complications
Pregnancy Outcome
Retrospective Studies
Megjelenés:European Journal of Obstetrics Gynecology and Reproductive Biology. - 101 : 2 (2002), p. 129-134. -
További szerzők:Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

9.

001-es BibID:BIBFORM020653
Első szerző:Kiss Emese (belgyógyász, immunológus)
Cím:Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients / Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G.
Dátum:2006
Megjegyzések:Systemic lupus erythematosus is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Objectives were to determine endothelial dysfunction with a non-invasive method in lupus patients and to analyse correlation with risk factors and atherosclerotic complications. Sixty-one SLE patients and 26 healthy age- and sex-matched control subjects were entered into the study. The diameters of brachial artery at rest, during reactive hyperaemia, and after glyceril trinitrate administration, as well as the intima-media thickness of the common carotid artery were measured using high-resolution B-mode ultrasonography. Demographic characteristics, lipid profile, paraoxonase activity, concentration of anti-phospholipid antibodies and anti-oxLDL were assessed together with atherosclerotic complications. The endothelium dependent vasodilation (FMD) was significantly impaired in SLE patients as compared to controls. The absolute difference of vessel diameter (Deltad) was 0.25+/-0.15 mm vs. 0.38+/-0.16 mm (p=0.001), and Deltad as in percent of the rest diameter was 7.31+/-5.2% vs. 9.86+/-3.87% (p=0.013) in lupus patients and controls, respectively. Nitrate mediated dilation (NMD) did not differ. FMD negatively correlated with age, systolic and diastolic blood pressure in SLE, but did not show significant correlation with the other examined parameters. However, FMD significantly differed between SLE patients with (5.54+/-4.36%) and without (8.81+/-5.28%) cardiovascular complications (p=0.01). The determination of flow-mediated vasodilation is a useful method to detect endothelial dysfunction in lupus patients, as reduced capacity of brachial artery may distinguish between SLE patients and healthy subjects, as well as lupus patients with and without atherosclerotic vascular complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Journal of Autoimmunity. - 27 : 4 (2006), p. 211-217. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Dér Henrietta (1977-) (orvos) Kocsis Zsolt (1987-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

10.

001-es BibID:BIBFORM001953
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus : results from a single center / Tarr T., Gyorfy B., Szekanecz E., Bhattoa H. P., Zeher M., Szegedi G., Kiss E.
Dátum:2007
Megjegyzések:As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age- and sex-matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity. Patients were 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95% CI 0.4-12.5) and cervix cancer (SIR 1.7, 95% CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
lupus
cancer
malignancy
lymphoma
azathioprine
chloroquine
corticosteroid
cyclophosphamide
cyclosporin A
immunosuppressive agent
methotrexate
adult
aged
bladder cancer
breast cancer
bronchus cancer
conference paper
controlled study
data analysis
data base
disease association
disease duration
female
gastrointestinal tumor
hematologic malignancy
human
Hungary
immunosuppressive treatment
incidence
male
morbidity
mortality
nonhodgkin lymphoma
ovary cancer
prevalence
retrospective study
skin cancer
standardization
systemic lupus erythematosus
uterine cervix cancer
Adult
Age of Onset
Aged
Humans
Hungary
Immunosuppressive Agents
Lupus Erythematosus, Systemic
Middle Aged
Neoplasms
Retrospective Studies
egyetemen (Magyarországon) készült közlemény
Megjelenés:Annals of the New York Academy of Sciences 1108 (2007), p. 76-82. -
További szerzők:Gyorfy Balázs Szekanecz Éva (1968-) (onkológus szakorvos) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

11.

001-es BibID:BIBFORM001209
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus / Tarr T., Lakos G., Bhattoa H. P., Szegedi G., Shoenfeld Y., Kiss E.
Dátum:2007
Megjegyzések:The objective of this study was to analyse whether primary antiphospholipid syndrome (PAPS) may precede and modify the characteristics of systemic lupus erythematosus (SLE). Out of the total 362 SLE patients in our service, 223 patients had antiphospholipid antibodies (aPL), of whom 110 met the criteria of antiphospholipid syndrome. In 26 cases (7.2%) PAPS appeared 5.5 years before the onset of lupus (PAPS+SLE Group). Their clinical findings were compared to lupus patients without (SLE only Group, n=26) and with secondary APS (SLE+SAPS Group, n=26). The prevalence of deep venous thrombosis, stroke/TIA, recurrent fetal loss, coronary heart disease and myocardial infarction was significantly higher in PAPS+SLE Group as compared to SLE only Group. The difference in prevalence of fetal loss (P=0.014) between PAPS+SLE and SLE+SAPS Groups was also recorded. On comparison to PAPS+SLE Group, patients without APS (SLE only Group) were younger at onset of lupus, with more frequent flares and a higher prevalence of WHO type III/IV nephritis (P=0.007), requiring higher doses of cyclophosphamide and corticosteroids. Lupus started in the form of PAPS in 7.2% of our SLE patients, who presented with more thrombotic and less inflammatory complications than in SLE patients without a prior or with a following secondary APS. Considering the long latency between the two diseases, PAPS may be a forerunner of lupus, but it may also coexist with SLE as an independent autoimmune disorder
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
association
PAPS
SLE
Association
phospholipid antibody
adolescent
adult
antiphospholipid syndrome
article
deep vein thrombosis
female
fetus wastage
heart infarction
human
ischemic heart disease
major clinical study
male
nephritis
priority journal
recurrent disease
school child
stroke
systemic lupus erythematosus
transient ischemic attack
Adolescent
Adult
Antiphospholipid Syndrome
Child
Female
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Megjelenés:Lupus 16 : 5 (2007), p. 324-328. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

12.

001-es BibID:BIBFORM001208
035-os BibID:PMID:17283584
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients / T. Tarr, G. Lakos, H. P. Bhattoa, Y. Shoenfeld, Gy. Szegedi, E. Kiss
Dátum:2007
Megjegyzések:The objective of this study was to characterize risk factors for thrombotic events in lupus patients. A total of 272 lupus patients were followed up for five years during which the presence of aPL antibodies [anticardiolipin (aCL), anti-beta2-glycoprotein I (abeta2GPI) and lupus anticoagulant (LAC)] were determined, and all thrombotic incidents and antithrombotic therapy-related data were collected. At baseline, three groups were constituted, an aPL- group with 107 aPL negative patients, an aPL- group with 81 aPL positive patients without clinical thrombosis and a secondary antiphospholipid syndrome (APS) group with 84 aPL- patients who met the Sapporo criteria. LAC was more common in the APS than the aPL- group (32.1% versus 9.9%, P < 0.001). The prevalence of clinical thrombotic events was significantly higher when all three types of aPL were present compared to only aCL positive cases. During follow up, aPL appeared in 7.5% of the aPL- group, and 2.8% of this group had thrombotic complications. In the aPL- group, thrombotic events reoccurred in 1.9% of those receiving antithrombotic prophylaxis and 6.9% of those without primary prophylaxis. Despite anticoagulant therapy, thrombotic events reoccurred in 8.3% of the APS group. These findings indicate that LAC, constant and cumulative presence of aPL and previous thrombosis are positive predictors for the development of thrombotic complication in lupus patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
antiphospholipid syndrome
primary prophylaxis
thrombosis
Primary prophylaxis
acetylsalicylic acid
beta2 glycoprotein 1 antibody
cardiolipin antibody
clopidogrel
coumarin
fibrinolytic agent
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
controlled study
disease duration
female
follow up
heart infarction
human
major clinical study
male
prevalence
priority journal
prophylaxis
risk assessment
risk factor
stroke
systemic lupus erythematosus
thrombocytopenia
thrombosis
Adult
Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Autoantigens
beta 2-Glycoprotein I
Cerebrovascular Accident
Female
Fibrinolytic Agents
Follow-Up Studies
Humans
Lupus Coagulation Inhibitor
Lupus Erythematosus, Systemic
Male
Middle Aged
Platelet Aggregation Inhibitors
Risk Factors
Thrombophilia
Thrombosis
egyetemen (Magyarországon) készült közlemény
Megjelenés:Lupus 16 : 1 (2007), p. 39-45. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Szerző által megadott URL
Borító:
Rekordok letöltése1 2